Does an FDA Establishment Registration mean a tissue bank's products are FDA-approved?

No. All tissue banks handling HCT/Ps are required to register their establishment and list their products with the FDA under 21 CFR Part 1271, which generates an FEI number. This registration is an administrative requirement and does not constitute FDA premarket approval, clearance, or endorsement of the product's safety or efficacy.

How can a practice manager verify a tissue bank's FDA status online?

Practice managers can use the FDA's public Human Cell and Tissue Establishment Registration (HCTERS) database to confirm that a facility's registration is active and covers the relevant tissue types. Additionally, administrators should search the FDA Data Dashboard and Warning Letters database to check for recent Form 483 observations, untitled letters, or Official Action Indicated (OAI) inspection classifications.

Why do a tissue bank's marketing brochures matter for our practice's compliance?

Under 21 CFR 1271.10(a)(2), whether a tissue product meets the criterion for 'homologous use' is determined in part by the labeling, advertising, and other indications of the manufacturer's objective intent. If a tissue bank markets a product with claims of treating systemic diseases or non-homologous conditions, the FDA may classify the product as an unapproved Section 351 drug, creating regulatory exposure for both the supplier and the purchasing clinic.

What testing documentation should accompany every shipment of Section 361 allografts?

Every lot should be backed by a Certificate of Analysis (CoA) or Certificate of Compliance confirming donor eligibility screening and negative infectious disease testing performed by a CLIA-certified lab using FDA-licensed donor screening tests. The documentation should also confirm microbiology/sterility testing (such as USP ), endotoxin limits, and clear lot traceability numbers alongside a tissue tracking record.

Is AATB accreditation required by the FDA for Section 361 compliance?

No, accreditation by the American Association of Tissue Banks (AATB) is voluntary and separate from federal FDA oversight. However, verifying AATB accreditation is a widely accepted best practice during vendor audits because it indicates the facility undergoes regular third-party inspections for tissue recovery, processing, and quality management standards.

Practice Operations · For practice managers

How to Audit Tissue Banks for FDA Section 361 Compliance

Published October 23, 2026

Primary Regulatory Framework: 21 CFR Part 1271
Section 361 Qualification Criteria: 4 Core Criteria
Audit Verification Pillars: Registration, CGTP, Labeling

Knowing how to audit tissue banks for FDA Section 361 compliance begins with demanding verifiable documentation across three operational areas: active FDA registration under 21 CFR Part 1271, Current Good Tissue Practice (CGTP) donor eligibility logs, and empirical evidence that the tissue meets minimal manipulation and homologous use standards. Because clinics face significant regulatory scrutiny and operational liability if a vendor's allografts drift into unapproved Section 351 biological drug classifications, relying on supplier sales claims alone is insufficient. Use this systematic vendor qualification workflow to evaluate supplier regulatory files before procuring allograft biologics for your practice.

Understanding the Regulatory Divide: Section 361 vs. Section 351

Before requesting documentation from a supplier, practice administrators must understand the statutory boundary established by the Public Health Service (PHS) Act and codified in 21 CFR Part 1271.

HCT/Ps regulated solely under Section 361 do not require premarket FDA approval because they meet four specific criteria found in 21 CFR 1271.10(a):

Minimal Manipulation: Processing does not alter the original relevant characteristics of structural tissue (relating to its utility for reconstruction, repair, or replacement) or the relevant biological characteristics of cells or nonstructural tissues.
Homologous Use Only: The product performs the same basic function or functions in the recipient as in the donor, as reflected by the labeling, advertising, and objective intent of the manufacturer.
No Combination with Other Articles: The HCT/P is not combined with another article, aside from water, crystalloids, or specific sterilizing, preserving, or storage agents that raise no new clinical safety concerns.
No Systemic Effect (with specific exceptions): The product does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function, unless it is for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.

If an allograft fails any one of these four criteria, it is regulated as a drug, device, or biological product under Section 351 of the PHS Act. Section 351 products require an active IND for clinical study or an approved BLA for commercial distribution. Understanding how to audit tissue banks for FDA Section 361 compliance is fundamentally about confirming that a vendor is not selling an unapproved Section 351 drug disguised as a Section 361 tissue.

Step-by-Step Checklist: How to Audit Tissue Banks for FDA Section 361 Compliance

Practice administrators should implement a standardized vendor qualification folder for every tissue bank or distributor in their supply chain. Use the following checklist before signing a purchasing agreement or placing an initial order.

1. Verify FDA Establishment Registration

Request the tissue bank’s FDA Establishment Identifier (FEI) number.
Cross-reference the FEI independently in the public FDA Human Cell and Tissue Establishment Registration (HCTERS) database.
Confirm that the registration status is "Active" and that the specific tissue types and processing functions match the products being offered to your practice.
Critical distinction: Note that an FDA registration is an administrative requirement, not an ”FDA approval.” Reject any vendor marketing materials that claim a Section 361 product is "FDA-approved."

2. Search FDA Enforcement and Compliance Databases

Check the FDA Data Dashboard and warning letter archives for the tissue bank’s legal name and any doing-business-as (DBA) entities.
Request the tissue bank’s most recent FDA inspection classification. Look for "No Action Indicated" (NAI) or resolved "Voluntary Action Indicated" (VAI) statuses. If an establishment has an open "Official Action Indicated" (OAI) status, pause onboarding.
Ask whether the manufacturer has received an FDA Form 483 (Inspectional Observations), an Untitled Letter, or a Warning Letter in the past five years. If they have, require written documentation of their Corrective and Preventive Action (CAPA) response and FDA close-out verification.

3. Audit Donor Eligibility and Testing Protocols (Subpart C)

Request a sample Certificate of Analysis (CoA) or Certificate of Compliance for the specific product line.
Verify that donor screening complies with 21 CFR 1271 Subpart C, including screening for relevant communicable disease agents and diseases (RCDADs) such as HIV-1/2, Hepatitis B and C, Treponema pallidum (syphilis), HTLV-I/II, and West Nile Virus.
Confirm that infectious disease testing is performed exclusively by laboratories certified under CLIA and using FDA-licensed, approved, or cleared donor screening tests.
For birth-tissue products (amniotic membrane, umbilical cord, Wharton's Jelly), confirm that tissue recovery protocols require healthy, full-term, planned cesarean sections with documented maternal informed consent.

4. Review Processing and CGTP Documentation (Subpart D)

Request a high-level summary of the tissue processing steps to verify minimal manipulation.
Confirm how the product is sterilized or aseptically processed, and require documentation of USP <71> sterility testing and endotoxin testing for each lot before release.
Verify whether the tissue bank holds voluntary accreditation from the American Association of Tissue Banks (AATB). While AATB accreditation does not replace FDA compliance, it demonstrates adherence to rigorous industry standards for tissue banking.

5. Scrutinize Labeling and Promotional Materials

Review the package insert, Instructions for Use (IFU), and all sales brochures.
Because the FDA evaluates "homologous use" based on the manufacturer’s objective intent, promotional materials that make systemic disease claims, anti-aging claims, or specific therapeutic promises can cause the FDA to classify the product as an unapproved Section 351 drug.
Ensure the labeling uses accurate, structural descriptors (e.g., protective covering, cushioning, or structural support) that align with the tissue's native anatomical role.

6. Validate Cold-Chain and Lot Traceability Workflows

Confirm shipping validation protocols: How does the tissue bank or distributor maintain required temperatures (cryogenic, dry ice, or ambient) during transit?
Verify that every vial or graft includes a unique donor/lot identifier and a recipient tracking log so your staff can comply with joint commission or state medical board traceability rules.

Clinical Considerations for Physicians and Medical Directors

While the practice manager handles vendor qualification and procurement documentation, the medical director and treating physicians must evaluate how tissue bank compliance intersects with clinical decision-making and malpractice risk.

For physicians across orthopedics, pain management, and regenerative medicine, clinical efficacy and regulatory compliance are closely linked. A tissue bank that cuts corners on CGTP standards may deliver products with inconsistent structural integrity, unverified sterility, or residual processing reagents that can trigger localized inflammatory responses in patients.

Furthermore, clinicians should review the peer-reviewed literature and white papers provided by the tissue bank. Does the vendor supply data characterizing the structural components of their specific allograft, or are they citing broad third-party studies on cultured mesenchymal stem cells that have no bearing on an acellular or minimally manipulated tissue product? Physicians should also ensure that patient informed consent forms clearly describe the nature of the allograft, its regulatory status as an HCT/P, and the distinction between homologous structural support and FDA-approved drug therapies.

Operationalizing Compliance: Role of the Distributor

Conducting primary audits on multiple tissue labs requires substantial administrative bandwidth. Many practices streamline this process by working with an established medical device and biologics distributor that performs upstream vendor vetting.

At Dallas Regenerative Solutions, our procurement team evaluates tissue bank registrations, CGTP controls, and quality management systems before adding any biologic to our catalog. However, working with a distributor does not absolve a clinical practice of maintaining its own compliance files. A compliant distributor should readily provide you with the underlying tissue bank’s FEI number, sample CoAs, package inserts, and storage SOPs so your practice’s audit binder remains complete and inspection-ready.

What This Means for Your Practice

Building a defensible biologics program requires proactive administrative hygiene. Practice managers can take these immediate steps this week:

Audit Current Inventory: Pull the package inserts and lot records for every allograft currently in your clinic’s freezer or storage cabinet, and verify each manufacturer’s active FEI status in the FDA HCTERS database.
Standardize Your Vendor Packet: Create a mandatory onboarding checklist requiring an FEI number, AATB status, sample CoA, and FDA inspection history before any new biologic vendor is presented to the medical director.
Align Marketing Copy: Review your practice’s website, patient brochures, and intake forms to ensure your clinic is not inadvertently making non-homologous or drug-like claims about Section 361 tissue products.
Establish a Lot Log SOP: Verify that your clinical staff logs the specific lot number, expiration date, and donor ID into the patient's electronic health record (EHR) at the time of administration, and returns tissue tracking cards to the tissue bank.

If your practice is evaluating new regenerative service lines or reviewing your current allograft supply chain, our team can help you review vendor documentation and procurement workflows. Reach out through our contact page to schedule an operational consultation with Dallas Regenerative Solutions.

Frequently asked questions

Does an FDA Establishment Registration mean a tissue bank's products are FDA-approved?: No. All tissue banks handling HCT/Ps are required to register their establishment and list their products with the FDA under 21 CFR Part 1271, which generates an FEI number. This registration is an administrative requirement and does not constitute FDA premarket approval, clearance, or endorsement of the product's safety or efficacy.
How can a practice manager verify a tissue bank's FDA status online?: Practice managers can use the FDA's public Human Cell and Tissue Establishment Registration (HCTERS) database to confirm that a facility's registration is active and covers the relevant tissue types. Additionally, administrators should search the FDA Data Dashboard and Warning Letters database to check for recent Form 483 observations, untitled letters, or Official Action Indicated (OAI) inspection classifications.
Why do a tissue bank's marketing brochures matter for our practice's compliance?: Under 21 CFR 1271.10(a)(2), whether a tissue product meets the criterion for 'homologous use' is determined in part by the labeling, advertising, and other indications of the manufacturer's objective intent. If a tissue bank markets a product with claims of treating systemic diseases or non-homologous conditions, the FDA may classify the product as an unapproved Section 351 drug, creating regulatory exposure for both the supplier and the purchasing clinic.
What testing documentation should accompany every shipment of Section 361 allografts?: Every lot should be backed by a Certificate of Analysis (CoA) or Certificate of Compliance confirming donor eligibility screening and negative infectious disease testing performed by a CLIA-certified lab using FDA-licensed donor screening tests. The documentation should also confirm microbiology/sterility testing (such as USP <71>), endotoxin limits, and clear lot traceability numbers alongside a tissue tracking record.
Is AATB accreditation required by the FDA for Section 361 compliance?: No, accreditation by the American Association of Tissue Banks (AATB) is voluntary and separate from federal FDA oversight. However, verifying AATB accreditation is a widely accepted best practice during vendor audits because it indicates the facility undergoes regular third-party inspections for tissue recovery, processing, and quality management standards.

Continue reading

FDA Section 361 vs 351 HCT/P Compliance Checklist
A structured operational guide and compliance checklist for medical practice managers navigating the regulatory distinctions between FDA Section 361 and Section 351 human cells, tissues, and cellular and tissue-based products (HCT/Ps).
How to Verify Section 361 Compliance for Allografts
Verifying Section 361 compliance for human tissue allografts requires confirming active FDA tissue establishment registration and evaluating the product against the four statutory criteria in 21 CFR 1271.10(a). This operational guide provides a step-by-step audit checklist for medical practice managers.
Informed Consent Requirements for Non-FDA Biologics
Understanding patient informed consent requirements for non-FDA-approved regenerative biologics is critical for practice compliance and risk management. This operational guide outlines required disclosures, workflow integration, and documentation standards.
Verifying Cold Chain Shipping Logs for Biologics
A practical guide for medical practice managers and clinical administrators on validating receiving temperature logs, maintaining tissue integrity, and documenting regulatory compliance for cryopreserved biologics.